New PSMAddition data show 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer
More durable, deeper PSA response in patients treated with Pluvicto plus standard…
The Benefits of Prostate Cancer Screening Outweigh the Harms, According to New Patient Guidelines From NCCN
Free, comprehensive guidebook shows how prostate cancer screening has largely deemphasized invasive…
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
February 23, 2026 17:10 ET | Source: Kyntra Bio FG-3246 and enzalutamide…
Curium Announces First Commercial Doses of PYLCLARI for Patients with Prostate Cancer in Poland
PYLCLARI® provides solutions to a wider patient group across Poland where there…
Profound Medical Celebrates The Hong Centers 200th Independent TULSA Procedure for Prostate Disease
TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN)…
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of64Cu-PSMA-I&T for Prostate Cancer in Japan
PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Curium Group announced today that…
Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY (Piflufolastat F 18) in Japan
BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) --…
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology…
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3…
